Microdosing Ibogaine to Avoid Heart Issues
Microdosing Ibogaine to Avoid Heart Issues
By Robert Korczynski
On Saturday, April 18, 2026, American medicine changed forever when President Trump signed Executive Order 14128, Accelerating Medical Treatments for Serious Mental Illness, expanding access to Right to Try medications from terminally ill patients to a new category called life-threatening diseases that includes depression and opiate addiction to reduce the rates of suicide and fatal overdoses. This expansion allows research into the power of psychedelics and specifically ibogaine’s ability in a "one-and-done" medical setting to cure people, like 80% of opioid addicts after one session according to Joe Rogan and over 90% after a second session.
Joe Rogan quoted this while standing directly behind the president's chair in the Oval Office because he's the reason this is happening. Rogan sent a text directly to Trump with the statistics on how ibogaine saves lives by ending opioid addiction and Trump said, "Sounds great. You want FDA approval? Let’s do it." Trump then coordinated with Bobby Kennedy, the Secretary of Health and Human Services, to bring Right to Try to ibogaine and other psychedelics.
Also standing behind the president was a line of combat veterans that had been cured of their opioid addictions by ibogaine. These veterans shared their stories and told how it was an addiction interrupter, how it helped them kick their habit of needing opioids and other substances, and how Traumatic Brain Injury (TBI) and chronic pain were the root of their initial opioid prescriptions. Navy SEAL Marcus Luttrell told the President, "It absolutely changed my life for the better," describing the treatment as offloading a "500-pound rucksack" of psychological trauma.
The 2024 Stanford University study led by Dr. Nolan Williams that these veterans participated in followed 30 Special Operations veterans and confirmed dramatic results, showing an 88% reduction in PTSD symptoms, an 87% reduction in depression, and an 81% reduction in anxiety within one month of treatment.
The current shift in federal policy is more than just a regulatory update; it is the dismantling of a more than 50-year-long suppression of dissociative medications. Since the 1970s the government has suppressed the dissociative PCP (Phencyclidine) due to a deep-seated fear of how much it could fundamentally change a person's perspective. Originally developed as an anesthetic, PCP was swept into the most restrictive scheduling categories not because of its physical toxicity, but because of its "psychotomimetic" effects, the way it allows a user to step outside of their own ego.
For over fifty years, the medical establishment preferred the "maintenance" model of daily pills that kept people functional but didn't actually resolve the underlying trauma. Dissociative medication was seen as too unpredictable because it didn't just mask symptoms; it forced a confrontation with the subconscious. This led to the demonization of the drug in the 1970s and 1980s. The suppression was intentional and relied on fear tactics. The government intentionally spread sensationalized horror stories to ensure the public was terrified of PCP, most notably the urban legend of the "PCP-crazed" individual who allegedly ate his friend's face after taking "horse tranquilizers." By pushing these narratives of cannibalism and madness, they created a cultural stigma that completely buried not only the drug's therapeutic potential in labs, but also the public's willingness to even try PCP on the street.
This suppression was fueled by the fact that dissociatives operate differently than standard psychedelics like psilocybin and LSD. With classic hallucinogens, the experience is famously dependent on "set, setting, and dosage," according to Timothy Leary and Richard Alpert. Your mindset, your physical surroundings, and the size of the dose all determine if it is a good trip or a bad trip, and there is no guarantee that there will be any sort of Life-Changing Awakening. However, with dissociatives like PCP and ibogaine, all it takes is a sufficiently large dose and every single user experiences 3 hours of hallucinations followed by 4 hours of introspective thought. As long as you have an effective dose, it doesn't matter about your mindset or your surroundings. This "forced awakening" is precisely why PCP was banned and demonized. It was too effective at changing the people that took it, and the government was afraid that everyone would wake up and have a revolution.
Today, that perspective is being inverted. Mostly because the police state is not afraid of PCP anymore, so now under the leadership of President Trump and Robert F. Kennedy Jr., the government is finally acknowledging that the very thing they feared, the ability of these drugs to radically rewire the human brain, is exactly what makes them the cure for treatment-resistant depression, PTSD, and addiction. By moving towards a one-and-done model of ibogaine use in clinical settings, we are finally ending the prohibition on the most complex and potentially life-saving molecules in medical history.
The doctors in the line behind the President were talking about only using it in a "one-and-done" clinical setting so they could monitor the heart. But according to Hamilton Morris, there may be a better way to dose ibogaine other than what he called a flood dose, what the doctors call one-and-done. Morris is famous for studying psychedelics and specifically dissociative psychedelics like PCP and ibogaine. He is the creator of the show Hamilton’s Pharmacopeia, which originally aired on Vice and is now available free on YouTube, where he has episodes on both PCP and ibogaine: "A Positive PCP Story" (Season 1, Episode 2) and "Synthetic Ibogaine – Natural Tramadol" (Season 3, Episode 4).
Three years ago Morris appeared on Joe Rogan's podcast talking about ibogaine. When Rogan asked him what he saw when he did ibogaine, Morris said he only took a very small 50 mg dose that didn't have any psychoactive effects because of his concerns over the cardiac risk. Clinical research has supported this caution; multiple doctors conducting low-dose trials have determined that doses up to 90 mg seem to present no significant cardiac issues in healthy subjects. Morris said people only did a flood dose because it was illegal and they had to travel to international clinics, and they didn't want to hang around for 2 months. He said that if it were ever legal in the United States, it would be better to take ibogaine over something like 2 months in smaller doses because of the cardiac risk. Up to 30 people have died at international clinics using flood doses over the last 20 years all in unlicensed clinics without heart monitors. Now that ibogaine is legal in the United States, Hamilton Morris should be brought in to establish the exact microdose over two months to avoid heart issues.
Morris said ibogaine is the most complex drug he has ever studied, and that it possesses at least six different modes of action, interacting with neuronal nicotinic receptors, dopamine transporters, serotonin transporters, NMDA receptors, and sigma receptor sites, all while acting as the trigger for a sixth mode of action: the GDNF protein release. Morris said not only is ibogaine an effective drug at stopping opioid addiction, it's also effective at stopping other kinds of addiction, and that is just "the tip of the iceberg."
GDNF has the ability in studies to treat Parkinson’s disease because it supports the survival and growth of dopamine-producing neurons, essentially acting as a structural repair for a condition that nothing else addresses. In one study (University of Otago, 2026), the use of ibogaine showed massive improvement in a 52-year-old Parkinson's patient; throughout the study, clinicians were monitoring her motor skills and checking points of feedback to ensure her safety. Because of the cardiac risks associated with the drug, they titrated her dose up from 5 mg to 75 mg over the span of about 10 weeks.
The titration and cardiac feedback means treatment for the millions of people suffering from depression and anxiety (including the 20% of all women said to be on antidepressants in the United States) would likely remain a clinical process. Hamilton Morris should be put in charge of establishing a standard dosing schedule for healthy adults to microdose ibogaine over the two months that he was talking about on the Joe Rogan podcast, whether it is titrated or not.
We must acknowledge that when veterans like Marcus Luttrell describe unloading a 500 lb rucksack of emotional baggage, they are describing the aftermath of a flood dose of 800 to 1,000 mg that causes a hallucinogenic 3-hour acute phase followed by 4 to 5 hours of deep introspective thought.
It remains to be seen if veterans would receive similar psychological benefits after microdosing for two months as they do after taking a flood dose, but that’s not the point. Maybe all veterans will benefit from a flood dose, but what about the 20% of all women that one of the doctors said were on antidepressants in the United States? Do all 27 million of them need a full hallucinogenic trip and 5 hours of introspection? Maybe they can just be rewired with some neuroplastic microdoses. Since a low dose titration is sub-perceptual and causes no hallucinations, it provides a safe clinical path for hardware repair without the necessity of a visionary trip.
Naturally the single largest lobby in Washington, D.C., Big Pharma, is going to fight this. In 2024 alone, this industry spent a staggering $382 million on lobbying, effectively funding the political campaigns of candidates on both sides of every race across the country. Their entire business model relies on the "maintenance" of illness through lifelong daily prescriptions. A one-and-done visit to an ibogaine clinic, or two months of lower doses of ibogaine that can end lifelong prescriptions is a financial disaster for companies that profit from thirty years of daily pills.
However, they aren't the only power in the room. The insurance companies, ranking as the number three or four largest lobby, spent $154 million in 2024 and have every reason to be the biggest advocates for this protocol. Insurance providers are looking at the bottom-line math. It costs approximately $12,000 a year for patients to stay on chronic maintenance medications, year after year. It could cost only $7,000 to have that patient stop using those products entirely within the next month or two through a supervised ibogaine one-and-done dose, or possibly a titrated or fixed microdose. While the pharmaceutical lobby fights to keep patients dependent, the insurance lobby will fight for the cure that clears their balance sheets. These two giants may just cancel each other out, leaving the path clear for the Trump RX solution.
The federal government should stop overcomplicating this with mandatory clinical stays and the one-and-done approach. Bring in Hamilton Morris, let him establish low-dose therapy and let Trump RX offer both flood doses and microdoses; that way we can move away from Big Pharma's business model of "maintenance" toward actual cures. If insurance companies want to pay for a flood dose, that is their business, but microdoses or low doses with or without titration should be available for all healthy adults. Ibogaine alone could break the pharmaceutical stranglehold on Americans by making healing psychedelics accessible under the Right to Try. Not everyone needs 3 hours of hallucination followed by 5 hours of introspection, but everyone deserves access to the rewiring that could come from Hamilton Morris's theoretical two-month regimen. If you feel like you have depression, anxiety, chronic pain, or if you are addicted to opiates, alcohol, or cigarettes and you want to stop, you can ask your doctor to participate in a high-dose ibogaine trial or inquire if a microdose, low-dose, or titration ibogaine trial is available. Not everyone wants or needs a hallucinogenic trip, but everyone deserves the ability to get rid of addiction, depression, and anxiety.
Citations
- Executive Order 14128 (April 18, 2026). "Accelerating Medical Treatments for Serious Mental Illness." [WhiteHouse.gov Archive]
- Morris, H. (2021). Joe Rogan Experience #1615. [Discussion on GDNF protein and ibogaine's 6 modes of action].
- Erny, T., Montenegro, E., et al. (2026). "Ibogaine for the treatment of Parkinson's disease: A case report." University of Otago. [80-day clinical titration documentation].
- Williams, N. et al. (2024). "Stanford Study on IBO and Special Operations Veterans." Nature Medicine. [Confirmed 88% PTSD symptom reduction].
- White House Fact Sheet (2026). [President Donald J. Trump Launches TrumpRx.gov to Lower Drug Prices].
- OpenSecrets.org (2024). [Lobbying Data: Pharmaceuticals ($382M) vs. Insurance ($154M)].
- Hamilton’s Pharmacopeia (2016). A Positive PCP Story (Season 1, Episode 2). [History of anesthetic PCP and federal scheduling].
- Hamilton’s Pharmacopeia (2021). Synthetic Ibogaine – Natural Tramadol (Season 3, Episode 4). [Gabonese addiction and the iboga molecule].
Using Iboga to Treat Addiction (Pharmacopeia S3, E4)
Comments
Post a Comment